Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enting

Showing results (211-220 of 232) with videos related to

Pageof 24
Sort By:
British Journal of Cancer|July 15, 2022
Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first waveBeth Russell, Charlotte Moss, Maria Monroy-Iglesias, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2018
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trialY Gao, B Weenink, M J van den Bent, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
JCO Global Oncology|November 4, 2022
IRONMAN: A Novel International Registry of Men With Advanced Prostate CancerLorelei A Mucci, Jacob Vinson, Theresa Gold, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Cancers|June 2, 2021
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer PatientsBeth Russell, Charlotte L Moss, Kieran Palmer, et al.
Frontiers in Oncology|September 9, 2020
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in LondonBeth Russell, Charlotte Moss, Sophie Papa, et al.
Cancers|January 21, 2022
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer CentreBeth Russell, Charlotte Moss, Eirini Tsotra, et al.
The Lancet. Oncology|July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialWalter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2021
Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort StudyCaroline Chau, Yvonne Rimmer Frcr, Ananya Choudhury PhD, et al.
Pageof 24

Showing results (211-220 of 232) with videos related to

Sort By:
Pageof 24
British Journal of Cancer|July 15, 2022
Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first waveBeth Russell, Charlotte Moss, Maria Monroy-Iglesias, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2018
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trialY Gao, B Weenink, M J van den Bent, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
JCO Global Oncology|November 4, 2022
IRONMAN: A Novel International Registry of Men With Advanced Prostate CancerLorelei A Mucci, Jacob Vinson, Theresa Gold, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Cancers|June 2, 2021
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer PatientsBeth Russell, Charlotte L Moss, Kieran Palmer, et al.
Frontiers in Oncology|September 9, 2020
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in LondonBeth Russell, Charlotte Moss, Sophie Papa, et al.
Cancers|January 21, 2022
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer CentreBeth Russell, Charlotte Moss, Eirini Tsotra, et al.
The Lancet. Oncology|July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialWalter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2021
Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort StudyCaroline Chau, Yvonne Rimmer Frcr, Ananya Choudhury PhD, et al.
Pageof 24